Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CFO James Patrick Kelly sold 9,155 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the sale, the chief financial officer now directly owns 144,721 shares of the company’s stock, valued at approximately $2,221,467.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at $15.25 on Friday. Vanda Pharmaceuticals Inc. has a 1-year low of $11.90 and a 1-year high of $18.99. The firm has a market capitalization of $671.93, a P/E ratio of -47.66 and a beta of 1.29.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. During the same period in the previous year, the company earned ($0.01) EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -0.44 EPS for the current year.

Several hedge funds have recently modified their holdings of VNDA. Russell Investments Group Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 109.3% during the second quarter. Russell Investments Group Ltd. now owns 93,995 shares of the biopharmaceutical company’s stock worth $1,532,000 after buying an additional 49,085 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 3.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 460,869 shares of the biopharmaceutical company’s stock worth $7,513,000 after buying an additional 16,183 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $1,137,000. Rhumbline Advisers lifted its holdings in shares of Vanda Pharmaceuticals by 14.2% during the second quarter. Rhumbline Advisers now owns 50,721 shares of the biopharmaceutical company’s stock worth $827,000 after buying an additional 6,299 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $538,000. Institutional investors own 88.43% of the company’s stock.

Several equities research analysts recently weighed in on VNDA shares. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer restated a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies boosted their target price on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.50.

ILLEGAL ACTIVITY WARNING: “James Patrick Kelly Sells 9,155 Shares of Vanda Pharmaceuticals Inc. (VNDA) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/james-patrick-kelly-sells-9155-shares-of-vanda-pharmaceuticals-inc-vnda-stock/1797173.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.